United States Patent [19]

Stone

[11] **Patent Number: 4,880,429**

[45] **Date of Patent: Nov. 14, 1989**

[54] **PROSTHETIC MENISCUS**

[76] Inventor: **Kevin R. Stone,** 133 Retiro Way, San Francisco, Calif. 94123

[21] Appl. No.: **75,352**

[22] Filed: **Jul. 20, 1987**

[51] **Int. Cl.**[4] **A61F 2/30**

[52] **U.S. Cl.** **623/18;** 623/20; 623/16; 128/DIG. 8; 530/356

[58] **Field of Search** ..... 128/1 R, DIG. 8; 530/356; 623/16, 18, 20

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,443,261	5/1969	Battista et al.	623/16
3,551,560	12/1970	Thiele	623/16 X
3,855,638	12/1974	Pilliar	623/16
4,055,862	11/1977	Farling	623/20 X
4,060,081	11/1977	Yannas et al.	128/156
4,085,466	4/1978	Goodfellow et al.	3/1.91
4,280,954	7/1981	Yannas et al.	260/123.7
4,291,013	9/1981	Wahlig et al.	623/16 X
4,344,193	8/1982	Kenny	623/20
4,350,629	9/1982	Yannas et al.	260/123.7
4,351,069	9/1982	Ballintyn et al.	623/16 X
4,378,224	3/1983	Nimni et al.	8/94.11
4,385,404	5/1983	Sully et al.	623/18
4,400,833	8/1983	Kurland	623/20 X
4,418,691	12/1983	Yannas et al.	128/156
4,448,718	5/1984	Yannas et al.	128/DIG. 8 X
4,458,678	7/1984	Yannas et al.	128/155
4,472,840	9/1984	Jefferies	623/16
4,502,161	5/1985	Wall	3/1.91
4,505,266	3/1985	Yannas et al.	128/1 R
4,542,539	9/1985	Rowe, Jr. et al.	623/16
4,544,516	10/1985	Hughes et al.	128/DIG. 8 X
4,614,794	9/1986	Easton et al.	530/356
4,627,853	12/1986	Campbell et al.	623/16

FOREIGN PATENT DOCUMENTS

1170001	7/1984	Canada .
1515963	6/1978	United Kingdom .
8303536	10/1983	World Int. Prop. O. .

OTHER PUBLICATIONS

Leenslag et al., (1986) *Biological and Biomechanical Performance of Biomaterials* (Christel et al., eds.) Elsevier Science Publishers B.V., Amsterdam, (1986), pp. 147–152.

Primary Examiner—Richard J. Apley
Assistant Examiner—David J. Bender
Attorney, Agent, or Firm—Lahive & Cockfield

[57] **ABSTRACT**

A prosthetic meniscus is disclosed which can be implanted in a humanoid knee, and which can act as a scaffold for regrowth of native meniscal tissues. The meniscus comprises a three dimensional array of collagen fibers interspersed with glycosaminoglycan molecules. The collagen fibers are present at a concentration of about 65 to 98 percent by dry weight, and the glycosaminoglycan molecules are present at a concentration of about 1 to 25 percent by dry weight. Cross-links are provided by at least a portion of the glycosaminoglycan molecules, and may consist of at least one of the group comprising chondroitan 4-sulfate, chondroitan 6-sulfate, keritan sulfate, dermatan sulfate, heparin sulfate, and hyaluronic acid.

12 Claims, 1 Drawing Sheet